Secher C, Brofeldt S, Mygind N
Allergy. 1983 Nov;38(8):565-70. doi: 10.1111/j.1398-9995.1983.tb04141.x.
Twenty-six pollen-allergic subjects participated in a double-blind, placebo-controlled trial of the protective effect of the calcium antagonist, verapamil, on allergen-provoked nasal symptoms. Intranasal verapamil, 1 mg. had a weak protective effect in that "tickling score" was 22% lower (P less than 0.01) and the number of sneezes 29% lower (nonsignificant) after verapamil as compared with placebo pretreatment. There were no differences with regard to nasal blockage or discharge. It is concluded that the verapamil spray used, cannot be recommended for clinical trials, but that further investigations of other formulations of calcium antagonist are justified in order to analyse the potential role of this type of drugs in the treatment of allergic rhinitis.
26名花粉过敏受试者参与了一项双盲、安慰剂对照试验，以研究钙拮抗剂维拉帕米对变应原诱发的鼻部症状的保护作用。鼻内给予1毫克维拉帕米具有微弱的保护作用，与安慰剂预处理相比，使用维拉帕米后“瘙痒评分”降低了22%（P<0.01），喷嚏次数降低了29%（无统计学意义）。在鼻塞或流涕方面没有差异。结论是，所使用的维拉帕米喷雾剂不推荐用于临床试验，但对钙拮抗剂的其他制剂进行进一步研究是合理的，以便分析这类药物在过敏性鼻炎治疗中的潜在作用。
